Glucose-6-Phosphate Dehydrogenase Antikörper (AA 351-450) (AbBy Fluor® 750)

Produktnummer ABIN5003599

Produktdetails anti-Glucose-6-Phosphate Dehydrogenase Antikörper (AbBy Fluor® 750)

Target: Glucose-6-Phosphate Dehydrogenase (G6PD)

Bindungsspezifität: AA 351-450

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Glucose-6-Phosphate Dehydrogenase Antikörper ist konjugiert mit AbBy Fluor® 750

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Kreuzreaktivität: Maus

Homologie: Human,Rat,Cow,Sheep,Horse,Rabbit

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human Glucose 6 Phosphate Dehydrogenase

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu Glucose-6-Phosphate Dehydrogenase

Target: Glucose-6-Phosphate Dehydrogenase (G6PD)

Andere Bezeichnung: Glucose 6 Phosphate Dehydrogenase (G6PD Produkte)

Hintergrund:

Synonyms: G6PD, G6PD_HUMAN, G6PD1, G6pdx, Glucose 6 phosphate 1 dehydrogenase, Glucose-6-phosphate 1-dehydrogenase, MET19, POS10, Zwf1p.

Background: Defects in G6PD are the cause of chronic non-spherocytic hemolytic anemia (CNSHA) . Deficiency of G6PD is associated with hemolytic anemia in two different situations. First, in areas in which malaria has been endemic, G6PD-deficiency alleles have reached high frequencies (1 % to 50 %) and deficient individuals, though essentially asymptomatic in the steady state, have a high risk of acute hemolytic attacks. Secondly, sporadic cases of G6PD deficiency occur at a very low frequencies, and they usually present a more severe phenotype. Several types of CNSHA are recognized. Class-I variants are associated with severe NSHA, class-II have an activity <10 % of normal, class-III have an activity of 10 % to 60 % of normal, class-IV have near normal activity.

Pathways: Regulation of Systemic Arterial Blood Pressure by Hormones